Community Bank N.A. Has $10.86 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Community Bank N.A. lifted its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 211,655 shares of the biopharmaceutical company’s stock after buying an additional 4,217 shares during the quarter. Bristol-Myers Squibb comprises about 1.4% of Community Bank N.A.’s investment portfolio, making the stock its 12th biggest position. Community Bank N.A.’s holdings in Bristol-Myers Squibb were worth $10,860,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. OFI Invest Asset Management acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth about $25,000. Milestone Investment Advisors LLC acquired a new stake in Bristol-Myers Squibb in the 3rd quarter worth about $27,000. Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares in the last quarter. Legacy Financial Group LLC acquired a new stake in Bristol-Myers Squibb in the 3rd quarter worth about $39,000. Finally, VisionPoint Advisory Group LLC raised its stake in Bristol-Myers Squibb by 300.5% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 553 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded down $0.13 during midday trading on Wednesday, hitting $48.86. 16,032,367 shares of the company traded hands, compared to its average volume of 15,532,586. The stock has a market cap of $99.03 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 1.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43. The firm’s fifty day moving average price is $51.22 and its 200-day moving average price is $51.31. Bristol-Myers Squibb has a 12 month low of $47.58 and a 12 month high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s revenue was up .6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.82 EPS. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.91%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on BMY shares. Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, April 15th. Wells Fargo & Company lifted their price objective on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.